newsfilter
← Earnings
Earnings Releases·

Design Therapeutics — Third Quarter 2026 Earnings Summary

  • Net loss widened to $20.3 million in Q3 2026 from $17.0 million in Q3 2025, driven by a 15% increase in total operating expenses to $22.2 million, while cash and investment securities declined to $208.6 million from $219.8 million at year-end 2025.
  • The company provided no new financial guidance but outlined key clinical milestones, including an update on DT-216P2 registrational plans in Q4 2026 and expected data readouts for DT-216P2, DT-818, and DT-168 throughout 2027.
  • All three primary clinical programs (RESTORE-FA for DT-216P2, Phase 1 for DT-818, and Phase 2 biomarker for DT-168) remain ongoing, with preclinical characterization advancing for the Huntington's disease program.
  • Management reiterated focus on evaluating DT-216P2 over longer treatment durations and preparing for next-stage development, while noting the company may need to raise additional funding to support business plans.
Company
DESIGN THERAPEUTICS INC
Sector
Healthcare
Industry
Biotechnology